Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.
暂无分享,去创建一个
[1] J. Avorn. Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. , 1984, The New England journal of medicine.
[2] L. Kuller,et al. Epidemiological Study of Sudden and Unexpected Deaths due to Arteriosclerotic Heart Disease , 1966, Circulation.
[3] W. Friedewald,et al. Clofibrate in ischemic heart disease. , 1972, Annals of internal medicine.
[4] H. Smits,et al. DRGs and the future of surgical practice. , 1984, The New England journal of medicine.
[5] W. Kannel. The role of cholesterol in coronary atherogenesis. , 1974 .
[6] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[7] K. McPherson,et al. Will payment based on diagnosis-related groups control hospital costs? , 1984, The New England journal of medicine.
[8] W. Kannel,et al. The unrecognized myocardial infarction. Fourteen-year follow-up experience in the Framingham study. , 1970, Geriatrics.
[9] J. Stamler,et al. George Lyman Duff Memorial Lecture. Lifestyles, major risk factors, proof and public policy. , 1978, Circulation.
[10] E. Cook,et al. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. , 1984, Annals of internal medicine.
[11] W. Kannel,et al. Prognosis after initial myocardial infarction: the Framingham study. , 1979, The American journal of cardiology.
[12] R. Levy. The decline in cardiovascular disease mortality. , 1981, Annual review of public health.